8HH Stock Chart & Stats
€9.60
€0.00(0.00%)
At close: 4:00 PM EST
€9.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€8.50 - €21.80
Previous CloseN/A
Volume0.00
Average Volume (3M)58.00
Market Cap
€1.02B
Enterprise Value€738.27
Total Cash (Recent Filing)€65.60M
Total Debt (Recent Filing)€138.40M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 11, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding46,847,816
10 Day Avg. Volume0
30 Day Avg. Volume58
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.67
Price to Sales (P/S)0.74
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.85
Revenue Forecast (FY)€602.76M
Bulls Say, Bears Say
Bulls Say
Business TransformationThe ongoing transformation continues to progress positively through the finalized Respiratory Health asset transfer, business efficiency programs, and creation of an AI Solutions portfolio.
Digestive Health PerformanceDigestive Health sales at $105.8M continued to outperform estimates, increasing ~12% Y/Y helped by the continued Neomed ENFit conversion tailwind.
Quarterly Performance And ReorganizationThe highlights of the quarter, such as strong NeoMed performance, free cash flow improvement, and Trident outperformance, set the stage for a solid growth platform as the company continues to reorganize and re-prioritize.
Bears Say
2025 GuidanceManagement's initial full-year 2025 guidance was light of Street expectations, calling for flat to slight declines in both revenue and earnings, reflecting a challenging market environment for some of its product categories, currency headwinds, and other macro factors.
Hyaluronic Acid BusinessThe hyaluronic acid injection business continues to be a sore spot with ongoing pricing pressures highlighted as a key factor underpinning the company’s below-Consensus initial 2025 guidance.
Market UncertaintiesLingering uncertainties surrounding tariffs, hyaluronic acid business disposition timing/impacts, and permanent CEO appointment incline the analyst to remain on the sidelines and reiterate a Hold rating.
Avanos Medical News
8HH FAQ
What was Avanos Medical’s price range in the past 12 months?
Avanos Medical lowest stock price was €8.50 and its highest was €21.80 in the past 12 months.
What is Avanos Medical’s market cap?
Avanos Medical’s market cap is €1.02B.
When is Avanos Medical’s upcoming earnings report date?
Avanos Medical’s upcoming earnings report date is Aug 11, 2026 which is in 11 days.
How were Avanos Medical’s earnings last quarter?
Avanos Medical released its earnings results on May 05, 2026. The company reported €0.192 earnings per share for the quarter, beating the consensus estimate of €0.122 by €0.07.
Is Avanos Medical overvalued?
According to Wall Street analysts Avanos Medical’s price is currently Overvalued.
Does Avanos Medical pay dividends?
Avanos Medical does not currently pay dividends.
What is Avanos Medical’s EPS estimate?
Avanos Medical’s EPS estimate is 0.14.
How many shares outstanding does Avanos Medical have?
Avanos Medical has 46,847,816 shares outstanding.
What happened to Avanos Medical’s price movement after its last earnings report?
Avanos Medical reported an EPS of €0.192 in its last earnings report, beating expectations of €0.122. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Avanos Medical?
Currently, no hedge funds are holding shares in DE:8HH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avanos Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:8HH Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.21%
Trailing 12-Months
Company Description
Avanos Medical
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.